Autobahn Therapeutics
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Thyroid hormone receptor-betaSmall molecule | Major Depressive DisorderBipolar Disorder |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
4 June 2026Topline resultElunetiromPhase 2 AMPLIFY-BD of elunetirom in bipolar depression met its primary endpoint
Autobahn Therapeutics · Source ↗
Financial reports
No financial reports recorded.